» Authors » Francisco Pasquau

Francisco Pasquau

Explore the profile of Francisco Pasquau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 103
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruiz-Alguero M, Alejos B, Garcia Yubero C, Riera Jaume M, Iribarren J, Asensi V, et al.
AIDS Res Hum Retroviruses . 2022 Mar; 38(6):433-440. PMID: 35357907
The present study sought to describe the use of generic drugs and single-tablet regimen (STR) de-simplification for the treatment of human immunodeficiency virus (HIV) infection among 41 hospitals from the...
2.
Solans-Laque R, Fraile G, Rodriguez-Carballeira M, Caminal L, Castillo M, Martinez-Valle F, et al.
Medicine (Baltimore) . 2017 Feb; 96(8):e6083. PMID: 28225490
The aim of this study was to describe the clinical characteristics of ANCA-associated vasculitides (AAV) at presentation, in a wide cohort of Spanish patients, and to analyze the impact of...
3.
Ramos J, Pasquau F, Galipienso N, Valero B, Navarro A, Martinez A, et al.
J Med Case Rep . 2015 Jul; 9:165. PMID: 26215452
Introduction: Whipple's disease is a rare infectious disease caused by Tropheryma whipplei with protean clinical manifestations. This infection may mimic chronic inflammatory rheumatisms. Case Presentation: We report two cases of...
4.
Ena J, Pasquau F, del Mar Lopez-Perezagua M, Martinez-Peinado C, Arjona F
Pathog Glob Health . 2014 Dec; 108(8):356-61. PMID: 25468205
Background: We anticipated that patients with HIV infection living in endemic areas were at greater risk of infection which can reactivate due to immunosuppression; therefore, we analyzed the prevalence of...
5.
Ena J, Amador C, Benito C, Pasquau F
HIV AIDS (Auckl) . 2012 Nov; 4:169-79. PMID: 23172991
We reviewed the current information available on nevirapine immediate- and extended-release formulations and its role in single-dose and combination antiretroviral therapy. Nevirapine was approved in 1996 and was the first...
6.
Ena J, Ruiz-de-Apodaca R, Pasquau F, Amador C, Benito C
Eur J Intern Med . 2011 Jan; 22(1):66-72. PMID: 21238897
Background: Sustained virologic response to peginterferon plus ribavirin reduces liver-related complications and mortality in patients co-infected with HIV and hepatitis C virus. Therefore, the presence of any barriers to start...
7.
Ena J, F Ruiz de Apodaca R, Amador C, Benito C, Pasquau F
Enferm Infecc Microbiol Clin . 2006 May; 24(4):232-7. PMID: 16725082
Background: We incorporated the latest available information to evaluate the net benefit of using resistance testing in HIV-infected patients with virological failure. Methods: Meta-analysis of randomized controlled trials comparing the...
8.
Amador C, Pasquau F, Ena J, Benito C, F Ruiz de Apodaca R
Med Clin (Barc) . 2005 Jun; 125(2):41-5. PMID: 15970181
Background And Objective: To describe the immunological, virological and clinical outcomes of HIV-infected patients who stop antiretroviral therapy (ART) and to identify the factors related to durability. Patients And Method:...
9.
Ena J, Benito C, Llacer P, Pasquau F, Amador C
Med Clin (Barc) . 2004 Jun; 122(19):721-6. PMID: 15171905
Background And Objective: Dyslipidemia, insulin resistance and body fat redistribution are respectively short and long-term complications of protease inhibitor-containing antiretroviral regimens. To establish whether differences in the type of antiretroviral...
10.
Ena J, Amador C, Benito C, Fenoll V, Pasquau F
Int J STD AIDS . 2003 Nov; 14(11):776-81. PMID: 14624743
We examined the risk and determinants of developing severe liver toxicity in 108 HIV-infected patients showing adherence to nevirapine- and efavirenz-containing regimens. Between January 1997 and December 2000, 70 patients...